Yeah it was a joke. Reporting that 2/3 improved is pointless and I would have preferred they omitted that comment. They could have commented on any observed changes to perfusion noted on MR but they didn't. This is basically a P1 trial so a long way still to go and I expect at some point the plan is to switch to the more variable afamelanotide dosing delivery in Prenumbra.
Having said that any update is pleasing
Ann: Afamelanotide well tolerated by first stroke patients, page-5
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.68 |
Change
-0.240(1.61%) |
Mkt cap ! $735.1M | |||
| Open | High | Low | Value | Volume |
| $14.75 | $14.92 | $14.65 | $503.5K | 34.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 448 | $14.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.74 | 149 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |